Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2013
12/17/2013US8609716 Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof
12/17/2013US8609702 Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use
12/17/2013US8609673 Vandetanib derivatives
12/17/2013US8609656 Heteroarylphenylurea derivative
12/17/2013US8609650 Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors
12/17/2013US8609613 Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides
12/17/2013US8609610 Inhibitors of the trypsin-like site of the proteasome and methods of use thereof
12/17/2013US8609092 Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
12/17/2013US8609081 Cyclodextrin-based polymers for therapeutics delivery
12/17/2013CA2758473C Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
12/17/2013CA2729343C Topical steroidal formulations
12/17/2013CA2667416C Process for making crystalline anhydrous docetaxel
12/17/2013CA2659774C Use of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
12/17/2013CA2612333C Inhibition of osteolytic lesions by src kinase inhibitors
12/17/2013CA2611893C Tetrahydroquinolines for use as modulators of the mitotic motor protein eg5
12/17/2013CA2597273C Proteasome inhibitors and methods of using the same
12/17/2013CA2427310C Imaging, diagnosis and treatment of angiogenesis-related diseases comprising ecsm4
12/17/2013CA2410883C Methods for isolating and using fungal hemolysins
12/15/2013CA2820236A1 Non-viral nanoparticle-based delivery system
12/12/2013WO2013185108A1 Methods and products related to lung cancer
12/12/2013WO2013185103A1 Macrocyclic inhibitors of flaviviridae viruses
12/12/2013WO2013185010A1 HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
12/12/2013WO2013184986A2 Methods and compositions for inhibiting angiogenesis
12/12/2013WO2013184878A1 Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
12/12/2013WO2013184876A1 Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
12/12/2013WO2013184681A1 Crystalline forms of an androgen receptor modulator
12/12/2013WO2013184621A1 Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
12/12/2013WO2013184572A1 Crystalline forms of a bruton's tyrosine kinase inhibitor
12/12/2013WO2013184202A1 Fbxo3 inhibitors
12/12/2013WO2013183578A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR
12/12/2013WO2013182580A1 Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
12/12/2013WO2013182546A1 Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
12/12/2013WO2013182519A1 Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
12/12/2013WO2013182503A1 Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods
12/12/2013WO2013181934A1 Polypeptide with function of synergistic targeted diagnosis and therapy of nasopharyngeal carcinoma, nanoparticles carrying same and use thereof
12/12/2013WO2013181888A1 Environmental responsive fundamental copolymer and preparation method therefor
12/12/2013WO2013181742A1 Methods of inhibiting rsk for treatment of breast cancer
12/12/2013WO2013118128A3 Cellular apobec3 proteins and modulators thereof for reglulating dna repair processes and treating proliferative diseases
12/12/2013US20130331564 Epothilone derivatives
12/12/2013US20130331310 Prodrug of an Ice Inhibitor
12/12/2013US20130330363 Method of vaccination
12/12/2013US20130330357 METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
12/12/2013US20130330356 METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
12/12/2013US20130330332 Treatment of pemphigus
12/12/2013DE112012001046T5 Stabile kolloidale Goldnanopartikel mit kontrollierbarer Oberflächenmodifizierung und Funktionalisierung Stable colloidal gold nanoparticles with controllable surface modification and functionalization
12/12/2013CA2876150A1 Compostions and methods for cancer immunotherapy
12/12/2013CA2876135A1 Modified fibronectin fragments or variants and uses thereof
12/12/2013CA2875986A1 Crystalline forms of a bruton's tyrosine kinase inhibitor
12/12/2013CA2875980A1 Binding agents that modulate the hippo pathway and uses thereof
12/12/2013CA2875767A1 Crystalline forms of an androgen receptor modulator
12/12/2013CA2875692A1 Macrocyclic inhibitors of flaviviridae viruses
12/12/2013CA2875305A1 Fbxo3 inhibitors
12/12/2013CA2874819A1 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
12/11/2013EP2671876A2 Pyrazine derivatives and their use as protein kinase inhbitors
12/11/2013EP2671597A1 Chimeric constructs between glioma-homing peptide and cell-penetrating peptides, gHoPe2
12/11/2013EP2671590A1 Tegafur-containing composition for single daily and alternate-day dosing
12/11/2013EP2671585A1 Therapeutic or prophylactic agent for cachexia
12/11/2013EP2671583A1 Externally-used drug for treating skin disorder and method for producing same
12/11/2013EP2671581A2 Compositions and methods for treating cancer
12/11/2013EP2671456A1 Novel use of maltotriosyl transferase
12/11/2013EP2671086A2 System and method for diagnosis and treatment
12/11/2013EP2670780A1 Cellulose-based nanoparticles for drug delivery
12/11/2013EP2670775A1 Anti-tace antibody molecules and their uses
12/11/2013EP2670753A1 Novel heterocyclic derivatives
12/11/2013EP2670749A1 New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
12/11/2013EP2670748A2 7-azaindole derivatives
12/11/2013EP2670740A1 Amidobenzothiazoles and process for the preparation thereof
12/11/2013EP2670739A1 Benzothiazole hybrids useful as anticancer agents and process for the preparation thereof
12/11/2013EP2670738A2 1,4 oxazines as bace1 and/or bace2 inhibitors
12/11/2013EP2670733A2 Hdac inhibitors and therapeutic methods using the same
12/11/2013EP2670440A1 Human antibodies and antibody-drug conjugates against cd74
12/11/2013EP2670437A2 Dosing for treatment with anti-egfl7 antibodies
12/11/2013EP2670435A1 Use of anti-dkk1 monoclonal antibody for treatment of liver cancer
12/11/2013EP2670426A2 Multimodal trail molecules and uses in cellular therapies
12/11/2013EP2670425A2 Ubiquitin interacting motif peptides as cancer therapeutics
12/11/2013EP2670419A1 Psa capture agents, compositions, methods and preparation thereof
12/11/2013EP2670405A1 Combinations comprising macitentan for the treatment of glioblastoma multiforme
12/11/2013EP2670401A1 Methods of using alk inhibitors
12/11/2013EP2650309A9 Conjugate of folate and antibody, preparation method and use thereof
12/11/2013EP2083858B1 Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
12/11/2013CN103443103A Novel Fusarisetin compounds, and use thereof
12/11/2013CN103443102A Bicyclic carboxamide inhibitors of kinases
12/11/2013CN103443100A Substituted 6-midazopyrazines for use as mps-1 and TKK inhibitors in the treatment of hyperproliferative disorders
12/11/2013CN103443098A Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
12/11/2013CN103443066A Ingenol-3-acylates I
12/11/2013CN103442768A Compositions and methods for treating cancer
12/11/2013CN103442767A Solid forms of a pharmaceutically active substance
12/11/2013CN103442736A Amatoxin-conjugates with improved linkages
12/11/2013CN103442715A A pharmaceutical composition comprising an HDAC inhibitor and a steroid and the use thereof.
12/11/2013CN103442710A Combination of checkpoint kinase 1 inhibitors and WEE1 kinase inhibitors
12/11/2013CN103442708A Therapeutic treatment
12/11/2013CN103436409A Making method of three-mushroom wine
12/11/2013CN103435815A Method for applying functionalized poly(amidoamine) dendrimer and nanometer compound thereof in gene transfection
12/11/2013CN103435715A Preparation method and application of vanadium complexes of oligosaccharides and derivatives thereof
12/11/2013CN103435695A Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
12/11/2013CN103435694A Smoothened多肽及使用方法 Smoothened polypeptide and methods of use
12/11/2013CN103435685A Monoclonal antibody capable of resisting fibrinogen-like protein, and application thereof
12/11/2013CN103435683A SPARC-derived cancer rejection antigen peptide and pharmaceutical comprising the same
12/11/2013CN103435672A Structure and synthesis of novel nucleoside phosphate prodrug containing substituted benzyl
12/11/2013CN103435657A Organic metal platinum compound with anti-cancer effect, and synthesis method thereof
1 ... 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 ... 2211